6 completed, 6 terminated, 1 active not recruiting. 6 Phase 1, 5 Phase 3, 1 Early Phase 1, 1 Phase 2.
By phase and status
Follow aducanumab: new trials by email Literature Review of aducanumab trials Research Report on aducanumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy Aducanumab, Exablate Model 4000 Type 2, Lecanemab - Mild Cognitive Impairment, Alzheimer Disease 1 Early Phase 1 Active not recruiting Ali Rezai 15 2022-07-14 2026-01-22 A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease Aducanumab, Placebo - Alzheimer's Disease Phase 3 Terminated Biogen 1027 2022-06-02 2025-04-23 A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers Aducanumab - Healthy Volunteer Phase 1 Completed Biogen 123 2022-02-01 2023-04-18 A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) Donanemab, Aducanumab - Mild Cognitive Impairment (MCI), Alzheimer Disease Phase 3 Completed Eli Lilly and Company 148 2021-11-16 2024-11-29 A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers Aducanumab - Healthy Volunteers Phase 1 Completed Biogen 30 2021-06-30 2023-04-13 A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 Aducanumab - Alzheimer's Disease Phase 3 Terminated Biogen 1696 2020-03-02 2025-02-21 A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities Aducanumab, Placebo - Cognitive Dysfunction, Alzheimer's Disease Phase 2 Terminated Biogen 52 2018-12-20 2021-09-16 Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants aducanumab - Alzheimer's Disease Phase 1 Completed Biogen 28 2016-05-01 2017-01-13 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease Aducanumab (BIIB037), Placebo - Alzheimer's Disease Phase 3 Terminated Biogen 1643 2015-09-15 2021-09-02 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease Aducanumab (BIIB037), Placebo - Alzheimer's Disease Phase 3 Terminated Biogen 1653 2015-08-13 2021-09-02 Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease Aducanumab, Placebo - Alzheimer's Disease Phase 1 Completed Biogen 21 2015-06-24 2020-08-21 Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb), Placebo - Alzheimer's Disease Phase 1 Terminated Biogen 197 2012-10-05 2020-08-03 Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease BIIB037, Placebo - Alzheimer's Disease Phase 1 Completed Biogen 53 2011-06-01 2015-03-23
Conditions studied Alzheimer Disease (10) · Cognitive Dysfunction (3) · Alzheimer disease type 1 (1)
Sponsors Biogen (11) · Ali Rezai (1) · Eli Lilly and Company (1)
Countries United States (12) · Japan (5) · Canada (4) · France (4) · Germany (4) · Italy (4) · Spain (4) · Australia (3) · Belgium (3) · Finland (3) · Poland (3) · South Korea (3) · Sweden (3) · United Kingdom (3) · Austria (2)
Top investigators Ali Rezai, MD, FAANS (1)
Results publications PMID 42841310 , PMID 34807243 , PMID 36600109 , PMID 38165296 , PMID 27582220 , PMID 29067304 , PMID 38567735 , PMID 40390253 , PMID 40413110 , PMID 40545559 , PMID 41804324
NIH funding 2015 (2), 2018 (1), 2019 (1)